CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02684461
NCT02684461Phase 2Completed
CompareCT.gov

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel After Standard First-Line Induction Chemotherapy in Advanced NSCLC

UNC Lineberger Comprehensive Cancer Center·interventional·Posted Feb 18, 2016·Updated Jun 3, 2022

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for Non Small Cell Lung Cancer. Completed, enrolled 20 participants across 5 sites.

Detailed Summary

The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer. Eligible subjects could be randomized to four (4) cycles of chemotherapy followed by immunotherapy, or immunotherapy followed by chemotherapy, or four cycles of chemotherapy plus immunotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 18, 2016
Enrollment StartSep 13, 2016
Primary CompletionNov 19, 2021
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 10.4 years ago

Interventions

Pembrolizumabdrug

Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles. Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.